HEMISPHERX BIOPHARMA, INC. (HEB) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition

On November 14, 2016, Hemispherx Biopharma, Inc. (the Company)
filed its quarterly report on Form 10-Q for the third quarter
ended September 30, 2016 and, thereafter, issued a press release
announcing its financial results for the third quarter then
ended. A copy of the press release is furnished as Exhibit 99.1
hereto and is incorporated herein by reference.

As noted in the press release, the Company will host a conference
call at 11:00 a.m. Eastern Standard Time (EST) on Tuesday,
November 15, 2016 to provide a general business update.
Hemispherx will respond to various stockholder questions
submitted prior to the call.

Conference Call Information

Item 7.01 Regulation FD Disclosure.

The information disclosed in Item 2.02 above is incorporated into
this Item 7.01. The information included in this Current Report
on Form 8-K (including the exhibit hereto) is being furnished
under Item 2.02, Results of Operations and Financial Condition,
Item 7.01, Regulation FD Disclosure and Item 9.01 Financial
Statements and Exhibits of Form 8-K. As such, the information
(including the exhibit) herein shall not be deemed to be filed
for the purposes of Section 18 of the Securities Exchange Act of
1934, as amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, nor shall it be incorporated by
reference into a filing under the Securities Act of 1933, as
amended, or the Exchange Act, regardless of any general
incorporation language in such filing, except as shall be
expressly set forth by specific reference in such a filing. This
Current Report (including the exhibit hereto) will not be deemed
an admission as to the materiality of any information required to
be disclosed solely to satisfy the requirements of Regulation FD.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

About HEMISPHERX BIOPHARMA, INC. (HEB)